<?xml version="1.0" encoding="UTF-8"?>
<p>In the current issue of the journal, Rashed et al. [
 <xref rid="b5-kjp-2019-01116" ref-type="bibr">5</xref>] investigated thyroid dysfunction in children with HCV infection receiving PegIFN plus ribavirin and showed that 28% of children (14 of 50) developed subclinical hypothyroidism. PegIFN-based therapies have various burdensome adverse reactions such as thyroid dysfunction. The incidence of thyroid dysfunction increases to 15%â€“40% with IFN use [
 <xref rid="b6-kjp-2019-01116" ref-type="bibr">6</xref>]. The types of thyroid dysfunction were subclinical hypothyroidism (50.7%), and so on such as hypo-, hyper-, and subclinical hyperthyroidism and thyroiditis [
 <xref rid="b7-kjp-2019-01116" ref-type="bibr">7</xref>].
</p>
